MX2021014287A - Nuevos antagonistas ciclicos del receptor b2 de bradiquinina. - Google Patents

Nuevos antagonistas ciclicos del receptor b2 de bradiquinina.

Info

Publication number
MX2021014287A
MX2021014287A MX2021014287A MX2021014287A MX2021014287A MX 2021014287 A MX2021014287 A MX 2021014287A MX 2021014287 A MX2021014287 A MX 2021014287A MX 2021014287 A MX2021014287 A MX 2021014287A MX 2021014287 A MX2021014287 A MX 2021014287A
Authority
MX
Mexico
Prior art keywords
disease
disorder
compound
bradykinin
receptor antagonist
Prior art date
Application number
MX2021014287A
Other languages
English (en)
Inventor
Christoph Gibson
Joern Saupe
Lars Ole Haustedt
Horst- Dieter Ambrosi
Original Assignee
Pharvaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharvaris Gmbh filed Critical Pharvaris Gmbh
Publication of MX2021014287A publication Critical patent/MX2021014287A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a un compuesto de acuerdo con la formula general (I), que actúa como un antagonista del receptor de bradiquinina (BK) B2; a una composición farmacéutica que contiene no o más compuestos de la invención; a una preparación de combinación que contiene al menos un compuesto de la invención y al menos otro principio farmacéuticamente activo adicional; y a los usos de dicho(s) compuesto(s), incluido el uso como medicamento. (ver Fórmula).
MX2021014287A 2019-05-23 2020-05-25 Nuevos antagonistas ciclicos del receptor b2 de bradiquinina. MX2021014287A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19176229 2019-05-23
PCT/EP2020/064379 WO2020234480A1 (en) 2019-05-23 2020-05-25 (r)-3-(chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)morpholine derivatives and related compounds as bradykinin (bk) b2 receptor antagonist for treating skin diseases

Publications (1)

Publication Number Publication Date
MX2021014287A true MX2021014287A (es) 2022-01-06

Family

ID=66668714

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014287A MX2021014287A (es) 2019-05-23 2020-05-25 Nuevos antagonistas ciclicos del receptor b2 de bradiquinina.

Country Status (13)

Country Link
US (1) US20220289730A1 (es)
EP (1) EP3956326B1 (es)
JP (1) JP7459235B2 (es)
CN (1) CN113906020B (es)
AR (1) AR118983A1 (es)
AU (1) AU2020277697B2 (es)
CA (1) CA3139228A1 (es)
ES (1) ES2958457T3 (es)
MX (1) MX2021014287A (es)
PL (1) PL3956326T3 (es)
TW (1) TWI827846B (es)
UY (1) UY38707A (es)
WO (1) WO2020234480A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38707A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Nuevos antagonistas cíclicos del receptor b2 de bradiquinina
AR118982A1 (es) * 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
WO2023180575A1 (en) * 2022-03-25 2023-09-28 Pharvaris Gmbh Solid composition comprising solubilised bradykinin b2-receptor antagonists
TW202345810A (zh) * 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
DE69533174T2 (de) 1994-10-27 2004-11-18 Fujisawa Pharmaceutical Co., Ltd. Pyridopyrimidinone, chinoline und anellierte n-heterozyklen als bradykinin-antagonisten
FR2737892B1 (fr) 1995-08-17 1997-10-24 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique
GB9602029D0 (en) 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
DE19609827A1 (de) 1996-03-13 1997-09-18 Hoechst Ag Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten
DE19610784A1 (de) 1996-03-19 1997-09-25 Hoechst Ag Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19612067A1 (de) 1996-03-27 1997-10-02 Hoechst Ag Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen
AUPN952696A0 (en) 1996-04-29 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
DE19712960A1 (de) 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
WO1999064039A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Bradykinin antagonists
HUP0104110A3 (en) 1998-10-21 2003-01-28 Astellas Pharma Inc Chuo Ku Vitreous form of known bradykinin antagonist and medicament containing it
FR2790260B1 (fr) * 1999-02-26 2001-05-04 Fournier Ind & Sante Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
CA2369544A1 (en) * 1999-04-02 2000-10-12 Robert W. Desimone Aryl and heteroaryl fused aminoalkyl-imidazole derivatives:selective modulators of bradykinin b2 receptors
GB9913079D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
AU2001229580A1 (en) 2000-01-18 2001-08-14 Nuerogen Corporation Substituted imidazoles as selective modulators of bradykinin b2 receptors
CA2364178C (en) 2000-12-05 2006-01-10 Yasuhiro Katsu N-benzenesulfonyl l-proline compounds as bradykinin antagonists
US6958349B2 (en) 2002-04-10 2005-10-25 Ortho-Mcneil Pharmaceuticals, Inc. Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
ITMI20021247A1 (it) 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
ITMI20041963A1 (it) 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
EP1741444A1 (en) 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
TWI407960B (zh) * 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
AR073304A1 (es) * 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
RU2015138443A (ru) 2013-03-14 2017-04-20 Шир Хьюман Дженетик Терапис, Инк. Способы лечения ангионевротического отека, опосредованного рецепторами брадикинина в2
WO2019101906A1 (en) 2017-11-24 2019-05-31 Pharvaris B.V. Novel bradykinin b2 receptor antagonists
UY38707A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Nuevos antagonistas cíclicos del receptor b2 de bradiquinina

Also Published As

Publication number Publication date
AU2020277697A1 (en) 2021-11-18
AU2020277697B2 (en) 2023-08-24
CN113906020B (zh) 2024-03-12
WO2020234480A1 (en) 2020-11-26
TW202110833A (zh) 2021-03-16
JP7459235B2 (ja) 2024-04-01
UY38707A (es) 2020-12-31
EP3956326B1 (en) 2023-06-28
PL3956326T3 (pl) 2024-01-22
EP3956326A1 (en) 2022-02-23
CA3139228A1 (en) 2020-11-26
AR118983A1 (es) 2021-11-17
EP3956326C0 (en) 2023-06-28
US20220289730A1 (en) 2022-09-15
ES2958457T3 (es) 2024-02-08
TWI827846B (zh) 2024-01-01
JP2022533487A (ja) 2022-07-22
CN113906020A (zh) 2022-01-07

Similar Documents

Publication Publication Date Title
MX2021014287A (es) Nuevos antagonistas ciclicos del receptor b2 de bradiquinina.
WO2019055966A3 (en) PYRIDAZINONES AND METHODS OF USE
KR101855358B1 (ko) 골암통증에서의 시그마 리간드의 용도
JP2005536475A5 (es)
JOP20190257A1 (ar) مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
WO2007049098A3 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
UA93872C2 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
MA35716B1 (fr) Formulations pharmaceutiques
WO2009009501A3 (en) Non-basic melanin concentrating hormone receptor-1 antagonists and methods
JP5911929B2 (ja) 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
KR20070036171A (ko) 선택적 노르아드레날린 재흡수 억제제와 ｐｄｅｖ 억제제의조합물
GB0620385D0 (en) Novel compounds
MX2011010732A (es) Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer.
MA37455B1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
CR20220036A (es) Derivados de 2h-indazol y su uso en el tratamiento de enfermedades
EA200870074A1 (ru) Производные 4,5-дигидро-(1н)-пиразола в качестве модуляторов каннабиноидного рецептора св1
MX2012001160A (es) Agonistas del receptor de esfingosina-1-fosfato.
WO2009096701A3 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
PH12020551297A1 (en) Compounds having s1p5 receptor agonistic activity
US10172814B2 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof